120
Participants
Start Date
April 7, 2021
Primary Completion Date
September 18, 2021
Study Completion Date
March 4, 2022
recombinant Ad5 vectored COVID-19 vaccine
This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
RBD-based protein subunit vaccine (ZF2001) against COVID-19
This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25μg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.
trivalent split influenza vaccine
This vaccine contains 15 μ g H1NI, 15 μ g H3N2 and 15 μ g B-series hemagglutinin, produced by Dalian Aleph Biomedical Co., Ltd.It is a liquid dosage form, 0.5 ml / bottle.
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing
Jiangsu Province Centers for Disease Control and Prevention
NETWORK